Contrasting Innovus Pharmaceuticals (INNV) & Its Peers

Innovus Pharmaceuticals (OTCMKTS: INNV) is one of 483 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Innovus Pharmaceuticals to related companies based on the strength of its valuation, risk, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Institutional & Insider Ownership

How to Become a New Pot Stock Millionaire

47.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 19.1% of Innovus Pharmaceuticals shares are held by company insiders. Comparatively, 15.0% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Innovus Pharmaceuticals has a beta of 3.96, meaning that its stock price is 296% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals’ competitors have a beta of 1.08, meaning that their average stock price is 8% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Innovus Pharmaceuticals and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innovus Pharmaceuticals 0 0 0 0 N/A
Innovus Pharmaceuticals Competitors 2758 8411 21205 565 2.59

As a group, “Pharmaceutical preparations” companies have a potential upside of 50.25%. Given Innovus Pharmaceuticals’ competitors higher probable upside, analysts clearly believe Innovus Pharmaceuticals has less favorable growth aspects than its competitors.


This table compares Innovus Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innovus Pharmaceuticals -73.78% -299.94% -62.83%
Innovus Pharmaceuticals Competitors -3,117.60% -153.52% -27.13%

Earnings & Valuation

This table compares Innovus Pharmaceuticals and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Innovus Pharmaceuticals $8.82 million -$6.50 million -3.49
Innovus Pharmaceuticals Competitors $2.03 billion $133.37 million -3.24

Innovus Pharmaceuticals’ competitors have higher revenue and earnings than Innovus Pharmaceuticals. Innovus Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


Innovus Pharmaceuticals competitors beat Innovus Pharmaceuticals on 6 of the 9 factors compared.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.

Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply